

## SUPPORTING INFORMATION

### **(NTA)<sub>1</sub>-Cy3**

N-(5-amino-1-carboxypentyl)iminodiacetic acid,<sup>1</sup> (Dojindo; 26 mg, 80  $\mu$ mol) was dissolved in 1.6 ml 0.1 M sodium carbonate and was added to Cy3 mono-succinimidyl-ester<sup>2</sup> ("Cy3 Mono-Reactive Dye"; Amersham-Pharmacia Biotech; 800 nmol). Following reaction for 1 h (with vortexing at 15-min intervals) at 25°C in the dark, the product was purified from excess N-(5-amino-1-carboxypentyl)iminodiacetic acid using a Sep-Pak C18 cartridge (Millipore; pre-washed with 10 ml acetonitrile and 10 ml water; washed with 20 ml water; eluted with 1 ml 60% methanol), dried, re-dissolved in 500  $\mu$ l water, and further purified by flash chromatography [silica gel, NH<sub>4</sub>OH:ethanol:water, 55:35:10, v/v/v; TLC  $r_f$  = 0.6]. The product was dried, re-dissolved in 2 ml water, and quantified spectrophotometrically ( $\epsilon_{550}$  = 150,000 M<sup>-1</sup> cm<sup>-1</sup>). Yield: 130 nmol, 16%.

### **(Ni<sup>2+</sup>:NTA)<sub>1</sub>-Cy3 (1a)**

NiCl<sub>2</sub> (Aldrich; 350 nmol in 3  $\mu$ l 0.01 N HCl) was added to (NTA)<sub>1</sub>-Cy3 (70 nmol in 2 ml water), and the solution was brought to pH 7 by addition of 0.8 ml 50 mM sodium acetate (pH 7), 200 mM NaCl. Following reaction for 30 min at 25°C in the dark, the product was purified using a Sep-Pak C18 cartridge (Millipore; procedure as above) and dried. ES-MS:  $m/e$  928.6 (calculated 928.2). Ni<sup>2+</sup> content [determined by performing analogous reaction with <sup>63</sup>NiCl<sub>2</sub> (New England Nuclear) and quantifying radioactivity in product by scintillation counting in Scintiverse II (Fisher)]: 0.92 mol Ni<sup>2+</sup> per mol.

### **(NTA)<sub>1</sub>-Cy5**

N-(5-amino-1-carboxypentyl)iminodiacetic acid,<sup>1</sup> (Dojindo; 26 mg, 80  $\mu$ mol) was dissolved in 800  $\mu$ l 0.1 M sodium carbonate and was added to Cy5 mono-succinimidyl-ester<sup>2</sup> ("Cy5 Mono-Reactive Dye"; Amersham-Pharmacia Biotech; 800 nmol). Following reaction for 1 h (with vortexing at 15-min intervals) at 25°C in the dark, the product was purified from excess N-(5-amino-1-carboxypentyl)iminodiacetic acid using a Sep-Pak C18 cartridge (Millipore; procedure as above), dried, re-dissolved in 500  $\mu$ l water, and further

purified by flash chromatography (silica gel, ethanol; TLC  $r_f$  = 0.2). The product was dried, re-dissolved in 100  $\mu$ l water, and quantified spectrophotometrically ( $\epsilon_{650}$  = 250,000 M<sup>-1</sup> cm<sup>-1</sup>). Yield: 77 nmol, 9.6%. ES-MS:  $m/e$  896.7 (calculated 896.3).

#### **(Ni<sup>2+</sup>:NTA)<sub>1</sub>-Cy5 (1b)**

NiCl<sub>2</sub> (Aldrich; 50 nmol in 0.5  $\mu$ l 0.01 N HCl) was added to (NTA)<sub>1</sub>-Cy5 (30 nmol in 1 ml water), and the solution was brought to pH 7 by addition of 0.5 ml 50 mM sodium acetate (pH 7), 200 mM NaCl. Following reaction for 30 min at 25°C in the dark, the product was purified using a Sep-Pak C18 cartridge (Millipore; procedure as above) and dried. ES-MS:  $m/e$  955.0 (calculated 954.2).

#### **(NTA)<sub>2</sub>-Cy3**

N-(5-amino-1-carboxypentyl)iminodiacetic acid,<sup>1</sup> (Dojindo; 26 mg, 80  $\mu$ mol) was dissolved in 1.6 ml 0.1 M sodium carbonate and was added to Cy3 bis-succinimidyl-ester<sup>2</sup> ("Cy3 Reactive Dye"; Amersham-Pharmacia Biotech; 200 nmol). Following reaction for 1 h (with vortexing at 15-min intervals) at 25°C in the dark, products were purified from excess N-(5-amino-1-carboxypentyl)iminodiacetic acid using a Sep-Pak C18 cartridge (Millipore; procedure as above), dried, re-dissolved in 200  $\mu$ l methanol, and purified by preparative TLC [silica gel, 1000 Å (Analtech); NH<sub>4</sub>OH:ethanol:water, 55:35:10, v/v/v]. Three bands were resolved, corresponding to (NTA)<sub>2</sub>-Cy3 ( $r_f$  = 0.2), (NTA)<sub>1</sub>-Cy3 mono acid ( $r_f$  = 0.5), and (NTA)<sub>2</sub>-Cy3 bis acid ( $r_f$  = 0.8). (NTA)<sub>2</sub>-Cy3 was eluted with 60% methanol, dried, re-dissolved in 2 ml water, and quantified spectrophotometrically ( $\epsilon_{550}$  = 150,000 M<sup>-1</sup> cm<sup>-1</sup>). Yield: 64 nmol, 8%. ES-MS:  $m/e$  1197.0 (calculated 1197.4).

#### **(Ni<sup>2+</sup>:NTA)<sub>2</sub>-Cy3 (2a)**

NiCl<sub>2</sub> (Aldrich; 350 nmol in 3  $\mu$ l 0.01 N HCl) was added to (NTA)<sub>2</sub>-Cy3 (70 nmol in 2 ml water), and the solution was brought to pH 7 by addition of 0.8 ml 50 mM sodium acetate (pH 7), 200 mM NaCl. Following reaction for 30 min at 25°C in the dark, the product was purified using a Sep-Pak C18 cartridge (Millipore; procedure as above) and dried. ES-MS:  $m/e$  1316.8 (calculated 1315.7). Ni<sup>2+</sup> content [determined

by performing analogous reaction with  $^{63}\text{NiCl}_2$  (New England Nuclear) and quantifying radioactivity in product by scintillation counting in Scintiverse II (Fisher)]: 1.4 mol  $\text{Ni}^{2+}$  per mol.

### **(NTA)<sub>2</sub>-Cy5**

N-(5-amino-1-carboxypentyl)iminodiacetic acid,<sup>1</sup> (Dojindo; 40 mg, 125  $\mu\text{mol}$ ) was dissolved in 0.8 ml 0.1 M sodium carbonate and was added to Cy5 bis-succinimidyl-ester<sup>2</sup> ("Cy5 Reactive Dye"; Amersham-Pharmacia Biotech; 800 nmol). Following reaction for 1 h (with vortexing at 15-min intervals) at 25°C in the dark, products were purified from excess N-(5-amino-1-carboxypentyl)iminodiacetic acid using a Sep-Pak C18 cartridge (Millipore; procedure as above), dried, re-dissolved in 200  $\mu\text{l}$  methanol, and purified in 100  $\mu\text{l}$  portions by preparative TLC [silica gel, 1000 Å (Analtech);  $\text{NH}_4\text{OH}$ :ethanol:water, 55:35:10, v/v/v]. Three bands were resolved, corresponding to (NTA)<sub>2</sub>-Cy5 ( $r_f$  = 0.2), (NTA)<sub>1</sub>-Cy5 mono acid ( $r_f$  = 0.6), and (NTA)<sub>2</sub>-Cy5 bis acid ( $r_f$  = 0.8). (NTA)<sub>2</sub>-Cy5 was eluted with 60% methanol, dried, re-dissolved in 2 ml water, and quantified spectrophotometrically ( $\epsilon_{650}$  = 250,000  $\text{M}^{-1} \text{cm}^{-1}$ ). Yield: 60 nmol, 7.5%.

### **(Ni<sup>2+</sup>NTA)<sub>2</sub>-Cy5 (2b)**

$\text{NiCl}_2$  (Aldrich; 90 nmol in 1  $\mu\text{l}$  0.01 N HCl) was added to (NTA)<sub>2</sub>-Cy5 (30 nmol in 1 ml water), and the solution was brought to pH 7 by addition of 0.5 ml 50 mM sodium acetate (pH 7), 70 mM NaCl. Following reaction for 30 min at 25°C in the dark, the product was purified using a Sep-Pak C18 cartridge (Millipore; procedure as above) and dried. ES-MS:  $m/e$  1341.0 (calculated 1341.7).

### **CAP-His<sub>6</sub>**

Plasmid pAKCRP-His<sub>6</sub> encodes CAP-His<sub>6</sub> under the control of bacteriophage T7 gene 10 promoter. Plasmid pAKCRP-His<sub>6</sub> was constructed from plasmid pAKCRP<sup>3</sup> by use of site-directed mutagenesis<sup>4</sup> to insert six His codons (CAC-CAC-CAC-CAC-CAC-CAC) after codon 209 of the *crp* gene.

To prepare CAP-His<sub>6</sub>, a culture of *Escherichia coli* strain BL21(DE3) (Novagen) transformed with pAKCRP-His<sub>6</sub> was shaken at 37°C in 1 L LB<sup>5</sup> containing 200 mg/ml ampicillin until OD<sub>600</sub> = 0.5, induced by addition of isopropyl-thio- $\beta$ -D-galactoside to 1 mM, and shaken an additional 3 h at 37°C. The culture was

harvested by centrifugation (4,500 x g; 15 min at 4°C), the cell pellet was re-suspended in 15 ml buffer A [20 mM Tris-HCl (pH 7.9), 500 mM NaCl, 5 mM imidazole], cells were lysed by sonication, and the lysate was cleared by centrifugation (30,000 x g; 30 min at 4°C). The sample was adjusted to 15 ml with buffer A, adsorbed onto 2 ml Ni<sup>2+</sup>-NTA agarose (Qiagen) in buffer A, washed with 12 ml buffer A containing 20 mM imidazole, and eluted with 6x1 ml buffer A containing 200 mM imidazole. Fractions containing CAP-His<sub>6</sub> were pooled, desalted twice into buffer B [40 mM Tris-HCl (pH 8), 100 mM NaCl, 1 mM dithiothreitol, 5% glycerol] by gel-filtration chromatography on NAP-10 (Amersham-Pharmacia Biotech), quantified spectrophotometrically ( $\epsilon_{278, \text{protomer}} = 20,000 \text{ M}^{-1} \text{ cm}^{-1}$ ), and stored in aliquots at -80°C. Yield: ~20 mg/L culture. Purity: >99%.

## **CAP**

CAP was prepared as in ref. 3.

## **DNA<sup>F</sup>**

DNA<sup>F</sup> was prepared as in ref. 3 (where it is referred to as "ICAP52<sup>F,-9</sup>").

## **Fluorescence anisotropy experiments**

Reaction mixtures [200 µl, in 100 µl quartz micro-cuvettes (Starna)] contained 50 nM **1a** or **1b**, or 10 nM **2a** or **2b**, in buffer C [40 mM Tris-HCl (pH 8), 100 mM NaCl, 1 mM dithiothreitol, 0.5 mM imidazole, 0.2 mM cAMP, 100 µg/ml bovine serum albumin, and 5% glycerol]. Reaction mixtures were titrated with 0-3 µM CAP-His<sub>6</sub> (or CAP) by successive addition of 0.5-4 µl aliquots of 2-4 µM CAP-His<sub>6</sub> (or CAP) in the same buffer. Fluorescence anisotropy was determined at the start of the titration and 5 min after each successive addition in the titration. All solutions were maintained at 25°C.

Fluorescence measurements were performed using a commercial steady-state fluorescence instrument (QM-1, PTI) equipped with T-format Glan-Thompson polarizers (PTI). Excitation wavelengths were 530 nm for **1a** and **2a**, and 630 nm for **1b** and **2b**; emission wavelengths were 570 nm for **1a** and **2a**, and 670 nm for **1b** and **2b**. Slit widths were 10 nm. Fluorescence emission intensities were corrected for background by subtraction

of fluorescence emission intensities for control reaction mixtures containing identical concentrations of CAP-His<sub>6</sub> or CAP but not containing **1a**, **1b**, **2a**, or **2b**.

Fluorescence anisotropy, A, was calculated using:<sup>6</sup>

$$A = (I_{VV} - GI_{VH}) / (I_{VV} + 2GI_{VH})$$

where  $I_{VV}$  and  $I_{VH}$  are the fluorescence intensities with the excitation polarizer at a vertical position and the emission polarizers at vertical and horizontal positions, respectively, and G is the grating correction factor.

Data were plotted as:

$$(A - A_0) / A_0$$

where A is the fluorescence anisotropy in the presence of the indicated concentration of CAP-His<sub>6</sub> or CAP, and  $A_0$  is the fluorescence anisotropy in the absence of CAP-His<sub>6</sub> or CAP. Equilibrium dissociation constants were calculated using non-linear regression.<sup>7</sup>

Similar results are obtained in experiments using buffers lacking imidazole or cAMP (data not shown).

### **FRET experiments: standard titrations**

Reaction mixtures [200  $\mu$ l, in 50  $\mu$ l quartz micro-cuvettes (Starna)] contained 5 nM DNA<sup>F</sup> and 50 nM CAP-His<sub>6</sub> (or CAP) in buffer C. Reaction mixtures were titrated with 0-3.2  $\mu$ M **2a** or **2b** by successive addition of 0.3-1.2  $\mu$ l aliquots of 30-300  $\mu$ M **2a** or **2b** in the same buffer. Fluorescence anisotropy was determined at the start of the titration and 5 min after each successive addition in the titration. All solutions were maintained at 25°C.

Fluorescence emission intensities, F, were measured using a commercial steady-state fluorescence instrument (QM-1, PTI) equipped with L-format Glan-Thompson polarizers (PTI) set at 54.7° ("magic angle"). Excitation wavelength was 480 nm; emission-wavelength range was 500-600 nm (titrations with **2a**) or 500-700 nm (titrations with **2b**); excitation slit width was 10 nm; emission slit width was 15 nm. Fluorescence emission intensities were corrected for background (by subtraction of fluorescence emission intensities for control

reaction mixtures containing identical concentrations of **2a** or **2b**, but not containing CAP-His<sub>6</sub> or CAP) and for dilution.

Efficiencies of FRET, E, were calculated as:

$$E = 1 - (F^{520,480}/F^{520,480}_o)$$

where  $F^{520,480}$  is the fluorescence emission intensity of the fluorescein label at the indicated concentration of **2a** or **2b**, and  $F^{520,480}_o$  is the fluorescence emission intensity of the fluorescein label at 0  $\mu$ M **2a** or **2b**.

Data were plotted as E vs. titrant concentration, and binding curves and equilibrium dissociation constants were calculated using non-linear regression.<sup>7</sup>

Donor-acceptor distances, R, were calculated using:<sup>8</sup>

$$E = R_o^6/(R_o^6 + R^6)$$

where  $R_o$  is the Förster parameter:

$$R_o \text{ (in } \text{\AA}) = 0.211 \times 10^{-5} (n^4 Q_D \kappa^2 J)^{1/6}$$

where n is the refractive index of the medium (1.4 for dilute protein solutions<sup>8</sup>),  $Q_D$  is the donor quantum yield in the absence of acceptor [0.4; measured using quinine sulfate in 0.1 N H<sub>2</sub>SO<sub>4</sub> as standard ( $Q_{QS} = 0.51$ )<sup>9</sup>],  $\kappa^2$  is the orientation factor relating the donor emission dipole and acceptor excitation dipole [approximated as 2/3 in this work--justified by the observed low fluorescent anisotropy of the donor<sup>3</sup>], and J is the spectral overlap integral of the donor emission spectrum and the acceptor excitation spectrum:

$$J = [\int F_D(\lambda) \epsilon_A(\lambda) \lambda^4 d\lambda] / [\int F_D(\lambda) d\lambda]$$

where  $F_D(\lambda)$  is the normalized corrected emission spectrum of donor,  $\epsilon_A(\lambda)$  is the molar extinction coefficient of acceptor, and  $\lambda$  is the wavelength.

Similar results are obtained in experiments using buffers lacking imidazole or cAMP (data not shown).

### FRET experiments: stoichiometric titrations

Stoichiometric titrations were performed analogously to standard titrations (preceding section), using reaction mixtures containing 0.6-2.6  $\mu\text{M}$  DNA<sup>F</sup>-CAP-His<sub>6</sub> [prepared by equilibration of DNA<sup>F</sup> with excess CAP-His<sub>6</sub> for 20 min at 25°C, followed by removal of unbound CAP-His<sub>6</sub> by filtration through Bio-Rex 70 (Bio-Rad; methods as in ref. 3)], and titrating with 0-12  $\mu\text{M}$  **2a** or **2b** by successive addition of 0.3-1.2  $\mu\text{l}$  aliquots of 30-300  $\mu\text{M}$  **2a** or **2b**.

Fluorescence emission intensities were corrected for dilution and background, and values of E were corrected for non-specific interactions (by subtraction of values of E for control reaction mixtures omitting CAP-His<sub>6</sub>). Corrected values of E were plotted as E/E<sub>sat</sub> vs. titrant concentration (where E<sub>sat</sub> is the E at saturating titrant concentrations).

### References

- (1) Hochuli, E.; Dobeli, H.; Schacher, A. *J. Chromatog.* **1987**, *411*, 177-184.
- (2) Mujumdar, R.; Ernst, L.; Mujumdar, S.; Lewis, C.; Waggoner, A. *Bioconjug. Chem.* **1993**, *4*, 105-111.
- (3) Kapanidis, A.N.; Ebright, Y.W.; Ludescher, R.; Chan, S.; Ebright, R.H. *J. Mol. Biol.* **2001**, *312*, 453-468.
- (4) Kunkel, T.; Bebenek, K.; McClary, J. *Meths. Enzymol.* **1991**, *204*, 125-138.
- (5) Miller, J. *Experiments in Molecular Genetics*; Cold Spring Harbor Laboratory: Cold Spring Harbor, New York, 1972.
- (6) Chen, R.; Bowman, R. *Science* **1965**, *147*, 729-732.
- (7) Gunasekera, A.; Ebright, Y.; Ebright, R. *J. Biol. Chem.* **1992**, *267*, 14713-14720.
- (8) Clegg, R. *Meths. Enzymol.* **1992**, *211*, 353-388.
- (9) Lillo, M.; Beechem, J.; Szpikowskak, B.; Sherman, M.; Mas, M. *Biochem.* **1997**, *36*, 11261-11272.